SEC Form 4 · accession 0001062993-15-006419
BIOSPECIFICS TECHNOLOGIES CORP · BSTC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas Wegman
Officer — President & CEO · Director · 10% Owner
Period of report
Nov 20, 2015
Accepted (ET)
Nov 24, 2015 · 5:48 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875622
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.001 par valueF1 | Nov 20, 2015 | S | 4,077 | $50.048 | D | 132,745 | D | |
| Common Stock, $0.001 par valueF2 | Nov 23, 2015 | S | 9,923 | $50.1039 | D | 122,822 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The selling price of $50.048 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $50.00 to $50.2401. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F2The selling price of $50.1039 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $50.00 to $50.15. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.